David A. Siegel Marker Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.26 - $0.46 $88,348 - $156,308	-339,800 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.37 - $1.0 $100,233 - $270,900	-270,900 Reduced 44.36%	339,800 $150,000
Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.72 $254,220 - $460,272	-267,600 Reduced 30.47%	610,700 $580,000
Q3 2021 Nov 15, 2021	SELL	$1.68 - $2.88 $800,184 - $1.37 Million	-476,300 Reduced 35.16%	878,300 $1.48 Million
Q2 2021 Aug 16, 2021	BUY	$1.88 - $3.56 $2.28 Million - $4.31 Million	1,210,900 Added 842.66%	1,354,600 $3.78 Million

Q1 2021 May 17, 2021	BUY	$1.47 - $3.29 $211,239 - $472,773	143,700 New	143,700 $322,000

472K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $438M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.